Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.